Supplementary MaterialsDocument S1. General, we demonstrate a GMP-compatible hESC-ECP that improved ischemic limb perfusion and increased local angiogenesis without engraftment, paving the way for translation of this therapy. and characterization. Open in a separate window Figure?1 Endothelial Differentiation of the Clinical-Grade hESC Line RC11 Differentiated cells analyzed on day 8 of the protocol predominantly co-expressed the endothelial markers CD31 and CD144 with few, if any, detectable residual pluripotent hESCs. (A) Representative flow cytometric analysis for the endothelial (left panels) and pluripotent markers (middle and right panels) with the appropriate isotype controls is shown. Cells were pre-gated for viable cells (FSC/SSC; 10,000 events) and doublet exclusion (FSC-A/FSC-H). (B) Day 8 hESC-ECP characteristics assessed against a target profile determined at the start of the study are shown; n?= 21 replicates. (C) qPCR-detected expression of selected pluripotent (NANOG, OCT4, and SOX2) and endothelial (CD31, KDR, and CD34) genes in differentiated RC11 cells shows the downregulation of pluripotency and acquisition of endothelial phenotype in comparison to mRNA from human umbilical vein endothelial cells (HUVECs) as a positive control. Data are shown as 2Ct 1,000 compared to the housekeeping gene -actin. hESC data are n?= 4 natural replicates assayed in triplicate, HUVEC n?= 3 in triplicate; *p? 0.05, **p 0.01, and ***p 0.001 denote significance in comparison to d0; ?p? 0.05, ??p 0.01, and ???p 0.001 denote degree of significance in comparison to HUVECs using one-way ANOVA with Tukeys post hoc test. All data stand for mean? SEM. To look for the identification of the rest of the 40% of cells which were not really dual positive for the quality endothelial mix of Compact disc31/Compact disc144, we evaluated expression of the wider -panel of surface area markers by fluorescence-activated cell sorting (FACS), having Rabbit polyclonal to PNPLA8 a concentrate on mesenchyme, pericyte, and hematopoietic cell markers. On day time 8 of differentiation, all cells positive for Compact disc144 were positive for Compact disc31 also; therefore, we evaluated combinations of Compact disc144 and extra markers. All the extra markers were indicated on either 95% or on 5% of cells, no bi-modal populations had been observed, and, consequently, markers were obtained as positive or adverse (Shape?2A). The pattern of staining dropped into 3 organizations (Shape?2B): markers typically observed on less mature endothelial cells and co-expressed?on only Compact Cytochalasin H disc144-positive cells (e.g., Compact disc34, Compact disc105, and Compact disc309); MSC and pericyte markers on all cells (e.g., Compact disc73, Compact disc44, Compact disc90, and Compact disc146); and hematopoietic/previously progenitors which were adverse on all cells (e.g., Compact disc14, Compact disc45, Compact disc56, and Compact disc133). Evaluation of mRNA from your day 8 inhabitants also proven downregulation of pluripotent-associated genes to identical levels to the people of human being umbilical vein endothelial cells (HUVECs). HUVECs had been chosen like a control because they are fetal endothelial cells and for that reason closer with regards to developmental age group to hESC-ECPs than adult ECs. Manifestation information of endothelial genes also shown the immature stage from the hESC-ECP; in hESC-ECP, CD31 and CD144 increased over time (8?days) to levels similar to those in HUVECs, whereas expression levels of KDR and CD34 increased to levels that were significantly higher than in HUVECs (Figures 1C and S1A). As the unmanipulated (non-purified cell product) produced by this protocol is the one intended for clinical use, the total heterogeneous cell population was used throughout this study and referred to as hESC-ECP due to the majority endothelial phenotype. Both the endothelial and non-endothelial (based on CD144 sorting) components of this Cytochalasin H heterogeneous population expressed genes associated with angiogenesis (Figure?S10). Open in a separate window Figure?2 Extended Surface Marker Analysis of Differentiated RC11 hESC-ECP An extended panel of surface markers known to be expressed in mesodermal, mesenchymal, hematopoietic, or pericyte differentiation of hESC was also assessed on the CD144/CD31 population Cytochalasin H (CD144+) and on those cells not expressing CD144 (CD144?). (A) Summaries of the data from 3 biological replicates are shown. (B) Examples of additional markers demonstrating 3 different patterns of expression are shown. Left panel, only CD144+ cells are positive for another marker (CD105); middle panel, CD144+ and CD144? cells are both positive for other marker (CD73); right panel, CD144+ and CD144? cells are both negative for other marker (CD133). EC, endothelial cell; HSC, hematopoietic stem cell; MSC, mesenchymal stromal cell; SC, stem cell. All data represent mean? SEM..